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Results

Materials and methods
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Fig. 6: NTC8382-1 (pUC origin) growth and yield profile of a
standard HyperGRO fed-batch fermentation using 3042°C step
induction at ~55 OD600. Host = NTC4862. Final plasmid yield was
2.2 g/L.
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Figure 5. Illustration of NTC’s HyperGRO inducible fed-batch
fermentation process using an exponential feeding strategy and
3042°C step or slow ramp temperature profile.
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Further host strain engineering to repress plasmid copy number during biomass growth resulted in pNano1
volumetric yield of 2.4 g/L after 42°C induction of high copy Nanoplasmid amplification (Fig. 8), which is near the
highest published fermentation yield for any plasmid.
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With years of expertise in plasmid production, NTC and VGXI have successfully implemented NTC’s HyperGRO™
fed-batch fermentation process for traditional plasmid and Nanoplasmid production at yields >1 g/L. However,
production of plasmids containing large antigen-coding inserts may have various challenges. Bacterial cell
machinery may not be able to produce high cell growth during fermentation due to a large gene insert in the
plasmid. A modified HyperGRO process was developed by NTC to overcome this cell growth inhibition. Plasmid
pNano1, a 6689 bp Nanoplasmid with a gene insert of 5018 bp, was successfully produced by VGXI using NTC’s
modified HyperGRO process, with high end cell density of OD600 90.1 and volumetric yield of 0.696 g/L.

160

Biomass (OD600)
Specific plasmid (mg/g DCW

Nature Technology Corporation’s (NTC’s) minimalized Nanoplasmid™ vectors utilize RNA-OUT (ROUT) antibiotic-free
selection and replace the large 1000 bp pUC replication origin with a novel, 300 bp, R6K-derived mini-origin (Fig.
1). Reduction of the spacer region linking the 5’ and 3’ ends of the transgene expression cassette to <500 bp
remarkably increases plasmid-mediated transgene expression. Host strains expressing heat-inducible, high copy
R6K replication (Rep) proteins have been developed for selection and propagation of Nanoplasmid. This is an
additional Nanoplasmid safety factor since mini-origin vectors can only replicate within the engineered Rep
protein-expressing E. coli host strain (Fig 2).

NTC Process Development

Plasmid (mg/L)

Plasmid based DNA vaccines are emerging as a promising alternative to traditional vaccines due to several
advantages, including faster production of DNA plasmids using E. coli. However, further increases in transgene
expression are needed to meet efficacy requirements for various non-viral gene therapy and DNA vaccination
applications. While existing minicircle DNA technology has been shown to offer improved levels and durations of
transgene expression by removal of the bacterial region from the plasmid, low manufacturing yields may be a
barrier to widespread use of minicircle DNA for vaccination.
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Fig. 8: pNano1 (NTC9385R Nanoplasmid) growth and yield
profile of a modified HyperGRO fed-batch fermentation. Feeding
for µ=0.26h-1; 3042°C slow ramp temperature induction. Host =
NTC1050811. 0.02% arabinose used in base medium to repress
growth phase copy number. Final Nanoplasmid yield was 2.4
g/L.

Fig. 7: pNano1 (NTC9385R Nanoplasmid) growth and yield
profile of a modified HyperGRO fed-batch fermentation. Feeding
for µ=0.26h-1; 3042°C slow ramp temperature induction. Host =
NTC821601. Final Nanoplasmid yield was 0.57 g/L.

VGXI Production and Purification of pNano1
in E. coli NTC821601
The faster exponential feeding (µ = 0.26 h-1
for Nanoplasmids was initiated at EFT
 6689 bp
(elapsed fermentation time) 15h accumulate
biomass and keep the plasmid copy number
Fig. 1: NTC9385R Nanoplasmid™ vector.
low. At EFT 26h, a linear feeding rate was
Fig. 2: Antibiotic-Free (AF) RNA-OUT-R6K plasmid
used with a slow ramp up of temperature
selection and propagation.
Plasmids
from 30°C to 42°C to slowly induce plasmid
production. At EFT 37.5h, a holding step at a
•pNano1 (6689 bp), Nanoplasmid consisting of 1671 bp NTC9385R backbone (Fig 1) with 5018 bp gene insert.
Fig. 9: Gel analysis of lysis, Anion Exchange and Hydrophobic Interaction
lower temperature was performed for 30
•NTC8382-1 (8023 bp), pUC origin, antibiotic-free (RNA-OUT) backbone with the same large gene insert.
Chromatography Process for pNano1 production in cell line NTC821601.
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Plasmid and Nanoplasmid production host strains
new plasmid molecules to the supercoiled
Assay
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•E. coli NTC4862: DH5α-derived with chromosomally integrated RNA-IN-SacB (levansucrase) expression cassette for
form, increasing yield and quality.
antibiotic-free, sucrose selectable pUC plasmids.
Concentration by A260
mg/mL
9.5
•E. coli NTC821601: DH5α-derived with chromosomally integrated RNA-IN-SacB (levansucrase) and temperature A high volumetric plasmid yield of 0.696 g/L Purity by A260/280
2.0
and specific plasmid yield of 2.77g/kg of cell Restriction
inducible R6K Rep expression cassettes for antibiotic-free, sucrose selectable R6K miniorigin Nanoplasmids.
CTS
•E. coli NTC1050811: DH5α-derived with chromosomally integrated RNA-IN-SacB (levansucrase) and temperature paste, and final OD600 of 90.1 was pH
7.3
achieved. At the end of the fermentation
inducible R6K Rep expression cassettes for antibiotic-free, sucrose selectable R6K miniorigin Nanoplasmids, with an
Host Cell Genomic
%
0.3
process, the cells were harvested using a
additional arabinose inducible Lambda cI repressor.
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%
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semi-continuous centrifugation process.
Host Cell RNA
%
≤0.1
Fermentation
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0.5
14L fermentors (New Brunswick Scientific) were employed at NTC and VGXI to perform 10L fermentations. A semi pNano1 was purified from the cell paste as Endotoxin
defined formulation was used for base and feed media, and 3042°C temperature profiles were used to induce described (Figs. 3 & 4), achieving impurity Forms by HPLC
levels
(HCP,
RNA,
gDNA,
endotoxin)
much
Total Supercoil
%
94
high copy plasmid amplification. Exponential feeding is used to control the specific growth rate (Fig. 5) during the
Total Circular
%
99
early fed-batch phase for biomass accumulation. With pUC-type plasmids, the specific growth rate is controlled at lower than FDA approved levels for clinical
use
(Table
1).
-1
µ = 0.12 h . However, with Nanoplasmids containing a large insert, this low growth rate results in early growth
Table 1: Quality Control Testing of Purified Nanoplasmid
inhibition due to excessive plasmid content. Controlling the specific growth rate at µ = 0.26 h-1 (near 30°C µmax)
keeps the Nanoplasmid copy number low to allow high biomass accumulation, before the temperature induced Conclusions
high copy Nanoplasmid amplification.
NTC’s Nanoplasmid™ is a next generation technology for plasmid production with a promising future. Nanoplasmid™
6689bp
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Figure 3. Schematic of the VGXI
manufacturing process from receipt of a
client plasmid through cGMP delivery of
filled vials.

Figure 4. Schematic of the VGXI cell lysis process using AIRMIX4 technology and a
scalable continuous capture method. (1) Cell Resuspension, (2) Alkaline Lysis Solution,
(3) Low Residence High Shear Static Mixer, (4) Lysis Hold Coil, (5) Neutralization
Precipitation Solution, (6) AIRMIX Column, (7) Crude Lysate, (8) Lysate Filtration, (9)
Filtered Lysate Holding Tank, (10) USP Purified Water, (11) Static Inline Mixer, (12) AEX
Membrane Load, (13) AEX Capture Membrane.

The VGXI Patented Airmix® Lysis Process is one of the most critical steps in the purification process. During this
step, the cell paste of pNano1 was suspended in the resuspension solution and mixed with the lysis solution using
a static mixer. The introduction of air bubbles at the precipitation step aids in low shear mixing and results in more
efficient removal of impurities like genomic DNA and host cell proteins. The lysis step was optimized for the
plasmids with the NTC backbone by increasing the incubation time of the crude lysate before filtering. The plasmid
concentration increases during this incubation, perhaps by diffusion of plasmid from the cell debris and better
reannealing of the plasmid strands. As a result, higher step yield was observed at the end of lysis.
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advantages include:
• Smaller spacer region  improved expression
 improved immunogenicity
• No antibiotic resistance marker.
• Much higher production yields (>2 g/L) compared to minicircles.
• Safety: engineered production host required; Nanoplasmids cannot replicate in endogenous or environmental bacteria.
• Smaller overall size  higher potency
 increased shear resistance during delivery
 more efficient downstream purification
Fermentation process modifications overcame cell growth inhibition to allow high yield production of Nanoplasmids.
Further host strain engineering resulted in Nanoplasmid production at similar or higher yields than pUC-origin plasmids (Fig.
8 vs. Fig 6.).
VGXI has effectively implemented HyperGRO process modifications for Nanoplasmid production at the 10L scale. As a
leader in the cGMP plasmid production, VGXI is committed to embolden innovation in the field to provide high quality
plasmid DNA products.
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